Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study

Background: The 2021 Canadian Cardiovascular Society guidelines recommend proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with atherosclerotic cardiovascular disease whose low-density lipoprotein cholesterol (LDL-C) concentration remains ≥ 1.8 mmol/L despite maxim...

Full description

Bibliographic Details
Main Authors: Milan Gupta, MD, G.B. John Mancini, MD, Rajvi J. Wani, PhD, Vineeta Ahooja, MD, Jean Bergeron, MD, MSc, Priya Manjoo, MD, A. Shekhar Pandey, MD, Maureen Reiner, MS, MA, Johnny Beltran, MD, MSc, Thiago Oliveira, MD, Erin S. Mackinnon, PhD
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:CJC Open
Online Access:http://www.sciencedirect.com/science/article/pii/S2589790X22000518

Internet

http://www.sciencedirect.com/science/article/pii/S2589790X22000518

Similar Items